AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Equillium Inc. (EQ)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.64

-0.06 (-8.56%)

At close: Jan 17, 2025, 3:59 PM

0.65

0.95%

After-hours Jan 17, 2025, 05:07 PM EST

undefined% (undefined)

Bid	0.64
Market Cap	22.81M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.12
PE Ratio (ttm)	-5.37
Forward PE	n/a
Analyst	Hold

Ask	0.65
Volume	119,020
Avg. Volume (20D)	184,050
Open	0.70
Previous Close	0.70
Day's Range	0.62 - 0.70
52-Week Range	0.56 - 3.25
Beta	undefined

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 12, 2018

Employees 45

Stock Exchange NASDAQ

Ticker Symbol EQ

Website https://equilliumbio.com

Analyst Forecast

According to 2 analyst ratings, the average rating for EQ stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 676.52% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago

-12.33%

Equillium shares are trading lower after the compa... Unlock content with Pro Subscription

2 months ago

-37.61%

Equillium shares are trading lower after the company announced Ono Pharmaceutical has made the business decision to allow the expiration of its option to acquire Equillium's rights to Itolizumab

News

2 months ago · businesswire.com

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat ...

2 months ago · zacks.com

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.